These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

222 related items for PubMed ID: 3897543

  • 1. Experimental manipulations and marrow-derived factors which affect the outcome of bone marrow transplantation across the H-2 barrier in lethally irradiated mice.
    Pierpaoli W, Kellerhals R, Buehler A, Sache E.
    J Clin Lab Immunol; 1985 Mar; 16(3):115-24. PubMed ID: 3897543
    [Abstract] [Full Text] [Related]

  • 2. Bone marrow transplantation with T-cell-depleted grafts. II. Reconstitution of immunohemopoietic functions in lethally irradiated mice transplanted with unseparated or T-cell-depleted bone marrow grafts disparate at minor histocompatibility antigens.
    Leshem B, Tsuberi BZ, Lebendiker Z, Anafi-Ayalon M, Shalit M, Weiss L, Slavin S, Kedar E.
    Transplantation; 1987 Jun; 43(6):814-7. PubMed ID: 2954282
    [Abstract] [Full Text] [Related]

  • 3. Donor-derived plasma transferrin facilitates the engraftment of xenogeneic (rat) bone marrow in irradiated mice.
    Pierpaoli W, Lesnikov V, Lesnikova M, Arrighi S.
    Bone Marrow Transplant; 1996 Jul; 18(1):203-7. PubMed ID: 8832016
    [Abstract] [Full Text] [Related]

  • 4. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM, Gorechlad J, Larsen CP, Waller EK.
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [Abstract] [Full Text] [Related]

  • 5. [The effect of iron carrier proteins on the transplantation of H-2 locus-incompatible bone marrow in irradiated mice].
    Pierpaoli W, Dall'Ara A, Neri P, Santucci A.
    Vopr Onkol; 1990 Dec; 36(10):1214-20. PubMed ID: 2251817
    [Abstract] [Full Text] [Related]

  • 6. Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation: effects of marrow dose.
    Koh CY, Welniak LA, Murphy WJ.
    Biol Blood Marrow Transplant; 2005 Apr; 11(4):252-9. PubMed ID: 15812390
    [Abstract] [Full Text] [Related]

  • 7. Altered donor and recipient Ly49+ NK cell subsets in allogeneic H-2d --> H-2b and H-2b --> H-2d bone marrow chimeras.
    Korten S, Wilk E, Gessner JE, Meyer D, Schmidt RE.
    J Immunol; 1999 Dec 01; 163(11):5896-905. PubMed ID: 10570275
    [Abstract] [Full Text] [Related]

  • 8. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR, Majewski D, Hanson G.
    Biol Blood Marrow Transplant; 1999 Dec 01; 5(4):222-30. PubMed ID: 10465102
    [Abstract] [Full Text] [Related]

  • 9. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach.
    Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST.
    J Immunol; 1996 Oct 01; 157(7):2820-9. PubMed ID: 8816385
    [Abstract] [Full Text] [Related]

  • 10. Effect of human transferrin on the engraftment of allogeneic bone marrow in various strans of lethally irradiated mice.
    Pierpaoli W.
    Nat Immun; 1992 Oct 01; 11(6):356-65. PubMed ID: 1477497
    [Abstract] [Full Text] [Related]

  • 11. Reconstitution ratio is critical for alloreactive T cell deletion and skin graft survival in mixed bone marrow chimeras.
    Taniguchi H, Abe M, Shirai T, Fukao K, Nakauchi H.
    J Immunol; 1995 Dec 15; 155(12):5631-6. PubMed ID: 7499847
    [Abstract] [Full Text] [Related]

  • 12. Donor double-negative Treg promote allogeneic mixed chimerism and tolerance.
    He KM, Ma Y, Wang S, Min WP, Zhong R, Jevnikar A, Zhang ZX.
    Eur J Immunol; 2007 Dec 15; 37(12):3455-66. PubMed ID: 18000953
    [Abstract] [Full Text] [Related]

  • 13. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE.
    Transplantation; 1990 Jan 15; 49(1):138-44. PubMed ID: 2137269
    [Abstract] [Full Text] [Related]

  • 14. Suppressor T cells in allogeneic bone marrow chimeras.
    Leshem B, Lebendiker Z, Weiss L, Slavin S, Kedar E.
    Bone Marrow Transplant; 1987 Aug 15; 2(2):123-32. PubMed ID: 2901877
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo cytokine-induced facilitation of immunohematopoietic reconstitution in mice undergoing bone marrow transplantation.
    Kedar E, Tsuberi BZ, Landesberg A, Anafi M, Leshem B, Gillis S, Urdal DL, Slavin S.
    Bone Marrow Transplant; 1988 Jul 15; 3(4):297-314. PubMed ID: 3048495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD, Drobyski WR, Truitt RL.
    Bone Marrow Transplant; 1993 Apr 15; 11(4):329-36. PubMed ID: 8485480
    [Abstract] [Full Text] [Related]

  • 18. Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.
    Pan Y, Luo B, Sozen H, Kalscheuer H, Blazar BR, Sutherland DE, Hering BJ, Guo Z.
    Transplantation; 2003 Jul 15; 76(1):216-24. PubMed ID: 12865813
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
    Zeis M, Uharek L, Glass B, Vosskötter W, Dreger P, Schmitz N, Steinmann J.
    Exp Hematol; 1998 Oct 15; 26(11):1068-73. PubMed ID: 9766447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.